Interferón beta para la esclerosis múltiple progresiva secundaria
Información
- DOI:
- https://doi.org/10.1002/14651858.CD005181.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 18 enero 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
| Conception of the study | Fippini G, Ebers G, Fredrikson S. |
| Design | Filippini G, La Mantia L, Ebers G, Fredrikson S. |
| Coordinator of the working group and contact Author | La Mantia L. |
| Draft the protocol | Filippini G, La Mantia L, Ebers G, Fredrikson S. |
| Check each draft version | La Mantia L , Vacchi L. |
| Check references and tables | La Mantia L, Vacchi L. |
| Enter data into RevMan (text) | La Mantia L, Vacchi L. |
| Enter data into RevMan (references) | La Mantia L, Vacchi L. |
| Preparation of data sheet for data extraction | La Mantia L. |
| Selection of studies | La Mantia L, Vacchi L, Filippini G. |
| Extract data from selected studies | La Mantia L, Vacchi L, Filippini G, Rovaris M. |
| Enter data into data sheet | La Mantia L , Vacchi L. |
| Carry out the analysis | La Mantia L, Vacchi L, Filippini G, Di Pietrantonj C. |
| Interpret the analysis | All the authors |
| Draft the final review | All the authors |
Sources of support
Internal sources
-
Department of Clinical Neurological Sciences, University of Western Ontario, Canada.
-
National Neurological Institute "Carlo Besta", Italy.
External sources
-
No sources of support supplied
Declarations of interest
Dr La Mantia has participated in clinical trials sponsored by SCHERING, and meetings sponsored by SCHERING, BAYER SERONO and BIOGEN.
Dr Fredrikson has received honoraria for lectures and educational activities sponsored by Bayer Schering Pharma, BiogenIdec, Merck Serono, Teva, Sanofi‐Aventis.
Prof Ebers, Dr Vacchi, Dr Filippini, Dr. Di Pietrantonj, Dr. Rovaris have no conflict of interest.
Acknowledgements
Phil You (Biogen Idec Wellesley, MA) (Cohen 2002 (IMPACT), Peter Cornelisse and Elisabetta Verdun di Cantogno (MerkSerono‐Ginevra) (SPECTRIMS 2001) for providing data from the primary studies.
Dr.Vasiliy Vlassov (Moscow Medical Academy) for his help in translation and analysis of Russian papers.
Deirdre Beecher Trials Search Coordinator for her support on papers retrieval and Liliana Coco Managing Editor for her precious technical assistance and support in drawing up the paper.
Version history
| Published | Title | Stage | Authors | Version |
| 2012 Jan 18 | Interferon beta for secondary progressive multiple sclerosis | Review | Loredana La Mantia, Laura Vacchi, Carlo Di Pietrantonj, George Ebers, Marco Rovaris, Sten Fredrikson, Graziella Filippini | |
| 2009 Jan 21 | Interferon beta for secondary progressive multiple sclerosis | Protocol | Loredana La Mantia, George Ebers, Sten Fredrikson, Graziella Filippini | |
| 2005 Jan 24 | Interferon beta for secondary progressive multiple sclerosis | Protocol | P A Rice G, George Ebers, Sten Fredrikson, Debbie Mason, Fabiana Tesser, Graziella Filippini, George PA Rice | |
Differences between protocol and review
Subgroups analysis was revised taking into account baseline characteristics of the patients.
